Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 10/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717224 | 0.89 | KDR (0.63) | CDK8KDRBRAFRAF1TRPV1 | |
| SCHEMBL282139 | 0.89 | RAF1 (0.54) | CDK8KDRHSD17B10BRAFRAF1 | |
| SCHEMBL282706 | 0.85 | KDR (0.61) | CDK8KDRBRAFRAF1TRPV1 | |
| SCHEMBL16507605 | 0.81 | CDK8 (0.61) | CDK8KDRBRAFRAF1MAPK14 | |
| SCHEMBL282377 | 0.79 | CDK8 (0.58) | CDK8KDRBRAFRAF1MAPK14 | |
| SCHEMBL282243 | 0.79 | KDR (0.66) | CDK8KDRBRAFMAPK14TNNI3K | |
| SCHEMBL718280 | 0.78 | PLA2G10 (0.49) | HSD17B10MAPTNPC1HTTRAB9A | |
| SCHEMBL15141035 | 0.75 | KDR (0.59) | CDK8KDRBRAFRAF1MAPT | |
| SCHEMBL939171 | 0.75 | CDK8 (0.70) | CDK8KDRBRAFRAF1MAPK14 | |
| SCHEMBL15141243 | 0.75 | KDR (0.55) | CDK8KDRBRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | claimed |
| EP-2428506-A1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | Jiangsu Provincial Institute Of Materia Medica Co. (CN) | 2012-03-14 | — | — | EP | claimed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | CDK8 2787/4885KDR 3633/4885HSD17B10 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.